Molecular Diagnosis on Circulating Tumor DNA of Non-Small Cell Lung Cancer (ANTiCIPe)

Rennes University Hospital

Status: Completed

Conditions: Stage IIIb and IV Non Small Cell Lung Cancer

Treatments: Other: laboratory biomarker analysis; Genetic: DNA Analysis; Other: Next Generation Sequencing

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT02169349

2014-A00426-41

Details and patient eligibility

About

The purpose of this study is to develop an ultra sensitive assay of mutation detection on circulating tumor DNA (ctDNA) for treatment, diagnosis and monitoring disease progression of Non-Small Cell Lung Cancer (NSCLC).

Enrollment: 100 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Signed written informed consent
• Male or female aged >= 18 years
• Stage IIIb and IV Non Small Cell Lung Cancer histologically confirmed

Exclusion criteria

• Tissue and plasma samples can not be provided for mutation analysis
• Unwilling or unable to provide informed consent
• Any serious medical condition that would interfere with the subject's safety